Cipla partners with MSN Laboratories for marketing and distribution of cancer dr

Cipla USA, Inc., a subsidiary of Cipla Ltd., has announced that it has secured rights from MSN Laboratories Pvt. Ltd. to market & distribute Capecitabine 150mg and 500mg tablets in the US. The product is available immediately.

The tablet is an AB-rated generic therapeutic equivalent version of Genentech’s Xeloda, and are indicated as a single agent for adjuvant treatment in patients with Dukes C colon cancer who have undergone complete resection of the primary tumour when treatment with fluoropyrimidine therapy alone is preferred, and also indicated for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy.

As per IQVIA, Xeloda and its generic equivalents had sales of approximately $178-mn for the 12-month period ending June 2018 in the US.

ANDA approval for antiretroviral drug

In another development, Cipla announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Atazanavir Caps (100mg, 150mg, 200mg, 300mg) from the US FDA.

The drug is AB-rated generic therapeutic equivalent version of BristolMyers Squibb Pharma Company’s, Reyataz, a protease inhibitor indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in patients with minimum age of six years and older weighing at least 15 kg.

According to IQVIA, Reyataz and its generic equivalents had US sales of approximately $324-mn for the 12-month period ending April 2018.